Navigation Links
Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Date:12/9/2008

SEATTLE, Dec. 9 /PRNewswire/ -- Omeros Corporation today announced favorable results from a Phase 1 vehicle-controlled study of OMS201, another of Omeros' PharmacoSurgery(TM) product candidates, for use during urological surgery.

The Phase 1 study of OMS201 enrolled patients undergoing endoscopic removal of urinary stones, and was designed to evaluate the systemic absorption and safety of the drug product. The pharmacokinetic data from this study show that systemic plasma levels of the active agents of OMS201 in patients were minimal and in most cases below the level of quantification. There were no serious adverse events.

"We continue to be encouraged by the progress being made in our OMS201 development program, and the completion of this study represents another successful milestone as we advance our PharmacoSurgery(TM) platform," stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "Based on these positive results, we intend to initiate a Phase 1/Phase 2 study evaluating the safety and preliminary efficacy of two higher concentrations of OMS201 in uroendoscopic surgery."

The Phase 1 study was a randomized, double-blind, vehicle-controlled and parallel-assigned study designed to evaluate the systemic absorption and safety of OMS201 in patients receiving primary treatment by endoscopic removal of urinary stones. OMS201, developed from Omeros' proprietary PharmacoSurgeryTM platform, is designed for use during urological surgery, including uroendoscopic procedures such as ureteroscopy, cystoscopy and minimally invasive prostate procedures. Added to standard irrigation solutions in urological surgery, OMS201 is delivered during the operation directly to the surgical site to inhibit surgically induced inflammation, pain and smooth muscle spasm.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgeryTM platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgeryTM clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at www.omeros.com.


'/>"/>
SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros and BlueCrest Announce $20 Million Debt Facility
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. Omeros Appoints David A. Mann to its Board of Directors
4. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
5. Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma
6. Genomic Health Announces Appointment of Ginger Graham to Board of Directors
7. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
8. Elsevier Announces Winners of 3rd Annual Scopus Young Indian Scientist Award
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
10. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
11. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... USA (PRWEB) , ... May 23, 2017 , ... Federal ... as well as an enabler of life-saving medical and other vital technologies — deserves ... . They joined others in the scientific community today in responding to the President’s ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... A recent ... the most troublesome and difficult to control weed in 12 categories of broadleaf crops, ... Almost 200 weed scientists across the U.S. and Canada participated in the 2016 survey, ...
(Date:5/23/2017)... ... May 22, 2017 , ... A new Technology Hot Topics ... this August will feature high-level speakers on quantum devices, graphene electronic tattoo sensors, ... Photonics, the largest multidisciplinary optical sciences meeting in North America, will run 6-10 ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Bacterial biofilms, ... polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter infections to ... biofilms is in the tens of billions of dollars per year, there is currently ...
Breaking Biology Technology:
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
Breaking Biology News(10 mins):